close

Agreements

1 230 231 232 233 234 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-10-10 Tigenix (Belgium) Finnish Red Cross Blood Service (Finland) ChondroCelect® single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults with or without concomitant asymptomatic cartilage lesions (ICRS grade I or II).           

distribution

Rheumatic diseases Distribution agreement
2011-10-10 Exonhit (France) Pfizer (USA - NY) Alzheimer’s disease biomarkers Alzheimer’s disease

R&D

Neurodegenerative diseases R&D agreement
2011-10-06 Boehringer Ingelheim (Germany) Gilead (USA) non-catalytic site integrase inhibitors (NCINIs) for HIV HIV-AIDS

licensing

Infectious diseases Licensing agreement
2011-10-06 Redbiotech (Switzerland) Merck&co (USA) technology platform rePAX™ undisclosed

R&D

undisclosed R&D agreement
2011-10-05 Bavarian Nordic (Denmark) National Cancer Institute (USA) new off-the-shelf product candidates for the treatment of multiple cancers and a new technology platform based on NCI\\\'s cancer vaccine technology research - R&D - licensing Cancer - Oncology R&D agreement
2011-10-05 Evotec (Germany) UCB (Belgium) research - R&D Immunology R&D agreement
2011-10-04 Vivalis (France) Delta-Vir (Germany) Newcastle Disease Virus (NDV) produced on Vivalis EB66® cell line

commercialisation
production
manufacturing

Cancer - Oncology - Infectious diseases Production agreement
2011-10-03 Warnex (Canada) Decode Genetics (Iceland) 10 deCODE Genetics\' DNA-based tests for assessing the risk of developing certain common diseases.

distribution

Cancer Oncology Cardiovascular diseases Ophtalmological diseaes Distribution agreement
2011-10-03 Merck KGaA, Merck Serono (Germany) Ono Pharmaceutical (Japan) Stimuvax® (BLP25 liposome vaccine) non-small cell lung cancer

licensing
development
commercialisation

Cancer - Oncology Licensing agreement
2011-09-29 Almirall (Spain) Nycomed (Switzerland) ebastine (Kestine®) allergic rhinitis, chronic idiopathic urticaria

licensing
supply

Allergic diseases - Dermatological diseases - Immunological diseases Licensing agreement
2011-09-29 Lundbeck (Denmark) Proximagen (UK) novel innovative therapies for serious diseases such as epilepsy, pain and inflammatory disorders serious diseases such as epilepsy, pain and inflammatory disorders

R&D

CNS diseases - Inflammatory diseases - Neurological diseases R&D agreement
2011-09-27 Hypha Discovery (UK) Ferrer Grupo (Spain) low molecular weight natural products to treat microbial infections microbial infections

R&D

Infectious diseases R&D agreement
2011-09-27 Lonza (Switzerland) Mesoblast (Australia) adult stem cell products

manufacturing
production

Regenerative medicine Production agreement
2011-09-27 Silence Therapeutics (UK) undisclosed top 10 pharma company DACC formulated siRNAs undisclosed

R&D

R&D agreement
2011-09-25 Biotec Pharmacon (Norway) Affymetrix (USA) shrimp alkaline phosphatase

Supply

Services contract
2011-09-22 Almirall (Spain) Proteros biostructures (Germany) small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases inflammatory diseases

R&D

Inflammatory diseases R&D agreement
2011-09-21 Sanofi Pasteur (France) University of California, San Diego (USA) acne vaccine and treatment Acne vulgaris

R&D

Dermatological diseases - Infectious diseases R&D agreement
2011-09-21 CMC Biologics (Denmark-USA) Inspiration Biopharmaceuticals (USA) IB1001 (intravenous recombinant factor IX (rFIX) product) treatment and prevention of bleeding in individuals with hemophilia B

manufacturing
production

Hematological diseases - Genetic diseases - Rare diseases Production agreement
2011-09-19 Merck KGaA, Merck Serono (Germany) Peptimmune (USA) PI-2301 mutliple sclerosis

licensing
development
commercialisation

Neurodegenerative diseases - Autoimmune diseases Licensing agreement
2011-09-19 NeuroVive Pharmaceutical (Sweden) Selvia (UK) new medicines and drug compounds targeting mitochondrial physiology and pathophysiology R&D